Soluble ST2: A new and promising activity marker in ulcerative colitis

被引:71
作者
Diaz-Jimenez, David [2 ]
Nunez, Lucia E. [2 ]
Beltran, Caroll J. [2 ,3 ]
Candia, Enzo [2 ]
Suazo, Cristobal [4 ]
Alvarez-Lobos, Manuel [5 ]
Gonzalez, Maria-Julieta [6 ]
Hermoso, Marcela A. [2 ]
Quera, Rodrigo [1 ,7 ]
机构
[1] Clin Las Condes, Gastroenterol Unit, Santiago 7591046, CL, Chile
[2] Univ Chile, Fac Med, Inst Biomed Sci, Disciplinary Program Immunol, Santiago 8380453, CL, Chile
[3] Univ Chile, Hosp Clin, Dept Clin Invest, Santiago 8380456, CL, Chile
[4] Clin Las Condes, Lab Oncol & Mol Genet, Colorectal Surg Unit, Santiago 7591046, CL, Chile
[5] Pontificia Univ Catolica Chile, Dept Gastroenterol, Santiago 8380074, CL, Chile
[6] Univ Chile, Fac Med, Inst Biomed Sci, Cell & Mol Biol Program, Santiago 8380453, CL, Chile
[7] Univ Chile, Hosp Clin, Gastroenterol Unit, Dept Internal Med, Santiago 8380456, CL, Chile
关键词
Inflammatory bowel disease; Ulcerative colitis; Soluble ST2; Biomarkers; INFLAMMATORY-BOWEL-DISEASE; C-REACTIVE PROTEIN; DESTABILIZED HEART-FAILURE; FECAL CALPROTECTIN; CROHNS-DISEASE; BLOOD LEUKOCYTES; INTESTINAL INFLAMMATION; AIRWAY INFLAMMATION; CLINICAL ACTIVITY; ACTIVITY INDEX;
D O I
10.3748/wjg.v17.i17.2181
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
AIM: To correlate circulating soluble ST2 (sST2) levels with the severity of ulcerative colitis (UC) and serum levels of pro-inflammatory cytokines, and to demonstrate the predictive power of sST2 levels for differentiation between active and inactive UC. METHODS: We recruited 153 patients: 82 with UC, 26 with Crohn's disease (CD) and 43 disease controls [non-inflammatory bowel disease (IBD)]. Subjects were excluded if they had diagnosis of asthma, autoimmune diseases or hypertension. The serum levels of sST2 and pro-inflammatory cytokines [pg/mL; median (25th-75th)] as well as clinical features, endoscopic and histological features, were subjected to analyses. The sST2 performance for discrimination between active and inactive UC, non-IBD and healthy controls (HC) was determined with regard to sensitivity and specificity, and Spearman's rank correlation coefficient (r). To validate the method, the area under the curve (AUC) of receiver-operator characteristic (ROC) was determined (AUC, 95% CI) and the total ST2 content of the colonic mucosa in UC patients was correlated with circulating levels of sST2. RESULTS: The serum sST2 value was significantly higher in patients with active [235.80 (90.65-367.90) pg/mL] rather than inactive UC [33.19 (20.04-65.32) pg/mL], based on clinical, endoscopic and histopathological characteristics, as well as compared with non-IBD and HC (P < 0.001). The median level of sST2 in CD patients was 54.17 (35.02-122.0) pg/mL, significantly higher than that of the HC group only (P < 0.01). The cutoff was set at 74.87 pg/mL to compare active with inactive UC in a multicenter cohort of patients. Values of sensitivity, specificity, and ability to correctly classify UC, according to activity, were 83.33%, 83.33% and 83.33%, respectively. The AUC of the ROC curve to assess the ability of this molecule to discriminate between active vs inactive UC was 0.92 (0.86-0.97, P < 0.0001). The serum levels of sST2 in patients with UC significantly correlated with endoscopic and histopathological scores (r = 0.76 and r = 0.67, P < 0.0001, respectively), and with the pro-inflammatory cytokine, tumor necrosis factor-a (r = 0.69 and r = 0.61, respectively, P < 0.0001). Interestingly, we found a direct correlation between total intestinal ST2 content and serum levels of sST2, adjusted to endoscopic activity score in patients with mild (r = 0.44, P = 0.004), moderate (r = 0.59, P = 0.002) and severe disease (r = 0.82, P = 0.002). Only patients with inactive UC showed no significant correlation (r = 0.45, P = 0.267). CONCLUSION: sST2 levels correlated with disease severity and inflammatory cytokines, are able to differentiate active from inactive UC and might have a role as a biomarker. (C) 2011 Baishideng. All rights reserved.
引用
收藏
页码:2181 / 2190
页数:10
相关论文
共 67 条
[1]
MECHANISMS OF DISEASE Inflammatory Bowel Disease [J].
Abraham, Clara ;
Cho, Judy H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (21) :2066-2078
[2]
Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells [J].
Allakhverdi, Zouna ;
Smith, Dirk E. ;
Comeau, Michael R. ;
Delespesse, Guy .
JOURNAL OF IMMUNOLOGY, 2007, 179 (04) :2051-2054
[3]
NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? [J].
Arnott, IDR ;
Nimmo, ER ;
Drummond, HE ;
Fennell, J ;
Smith, BRK ;
MacKinlay, E ;
Morecroft, J ;
Anderson, N ;
Kelleher, D ;
O'Sullivan, M ;
McManus, R ;
Satsangi, J .
GENES AND IMMUNITY, 2004, 5 (05) :417-425
[4]
Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic Load [J].
Bartunek, Jozef ;
Delrue, Leen ;
Van Durme, Frederik ;
Muller, Olivier ;
Casselman, Filip ;
De Wiest, Bart ;
Croes, Romaric ;
Verstreken, Sofie ;
Goethals, Marc ;
de Raedt, Herbert ;
Weinberg, Ellen O. ;
Vanderheyden, Marc ;
Sarma, Jaydeep ;
Joseph, Lija .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (25) :2166-2174
[5]
Characterization of the Novel ST2/IL-33 System in Patients with Inflammatory Bowel Disease [J].
Beltran, Carol J. ;
Nunez, Lucia E. ;
Diaz-Jimenez, David ;
Farfan, Nancy ;
Candia, Enzo ;
Heine, Claudio ;
Lopez, Francisco ;
Julieta Gonzalez, Maria ;
Quera, Rodrigo ;
Hermoso, Marcelo A. .
INFLAMMATORY BOWEL DISEASES, 2010, 16 (07) :1097-1107
[6]
Carroccio A, 2002, CLIN CHEM, V48, P1546
[7]
Inflammatory bowel disease: Genetic and epidemiologic considerations [J].
Cho, Judy H. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (03) :338-347
[8]
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease [J].
Costa, F ;
Mumolo, MG ;
Ceccarelli, L ;
Bellini, M ;
Romano, MR ;
Sterpi, C ;
Ricchiuti, A ;
Marchi, S ;
Bottai, M .
GUT, 2005, 54 (03) :364-368
[9]
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD [J].
Daperno, M ;
D'Haens, G ;
Van Assche, G ;
Baert, F ;
Bulois, P ;
Maunoury, V ;
Sostegni, R ;
Rocca, R ;
Pera, A ;
Gevers, A ;
Mary, JY ;
Colombel, JF ;
Rutgeerts, P .
GASTROINTESTINAL ENDOSCOPY, 2004, 60 (04) :505-512
[10]
Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath [J].
Dieplinger, B. ;
Gegenhuber, A. ;
Haltmayer, M. ;
Mueller, T. .
HEART, 2009, 95 (18) :1508-1513